CD18 Chimeric Recombinant Rabbit Monoclonal Antibody (1B4), Invitrogen™

Description

• Specificity: Specific to the beta chain of the leukocyte integrin beta-2 family
• This is found in LFA-1, Mac-1 and p150.95 among others
• Binds an epitope distinct from the C3bi binding site
• Has been shown to recognise both the human and Rhesus monkey antigen
• Preparation: Blood was obtained from 4 helathy donors and the mononuclear cells harvested and grown
• A BALB/c mouse was injected with 10^6 monocytes three times at monthly intervals, and four times with 5x10^6 monocytes oon each of the four days before fusion
• The spleen cells were then fused to P3U1 myeloma cells to generate hybridomas and RIA was used to identify lines of interest
• CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes
• CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling
• CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18)
• In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts
• Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease
• CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis
• Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1)
• Two transcript variants encoding the CD18 protein have been identified.